Dual-targeting mechanism designed for robust Blood-Brain Barrier (BBB) crossing. Enables highly efficient systemic delivery beyond brain vasculature directly into deep parenchymal cells.
High-efficiency plug-and-play loading of oligonucleotides (ASO, siRNA) directly to the NNP surface.
Stable intracellular transport and functional release of complex macromolecules including therapeutic enzymes.
Engineered to ensure robust endosomal escape, enabling complete cytoplasmic delivery of therapeutic payloads.
I-NNP targets CD47-high diseased tissues in inflammation, fibrosis, and autoimmunity, combining CD47-SIRPα blockade with therapeutic payload delivery in one nanoparticle.
I-NNP uses surface SIRPα to bind CD47-high diseased cells, enabling active homing to inflammatory, fibrotic, and autoimmune tissue sites.
By blocking the CD47-SIRPα "don't eat me" signal, I-NNP adds immune-modulating activity directly into the delivery carrier.
The same CD47-guided carrier can be adapted with ASO, siRNA, or protein payloads to build disease-specific therapeutic pipelines.
Dual-targeting mechanism designed for robust Blood-Brain Barrier (BBB) crossing. Enables highly efficient systemic delivery beyond brain vasculature directly into deep parenchymal cells.
High-efficiency plug-and-play loading of oligonucleotides (ASO, siRNA) directly to the NNP surface.
Stable intracellular transport and functional release of complex macromolecules including therapeutic enzymes.
Engineered to ensure robust endosomal escape, enabling complete cytoplasmic delivery of therapeutic payloads.
I-NNP targets CD47-high diseased tissues in inflammation, fibrosis, and autoimmunity, combining CD47-SIRPα blockade with therapeutic payload delivery in one nanoparticle.
I-NNP uses surface SIRPα to bind CD47-high diseased cells, enabling active homing to inflammatory, fibrotic, and autoimmune tissue sites.
By blocking the CD47-SIRPα "don't eat me" signal, I-NNP adds immune-modulating activity directly into the delivery carrier.
The same CD47-guided carrier can be adapted with ASO, siRNA, or protein payloads to build disease-specific therapeutic pipelines.
